Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

[EX Q]: Young people frequently say that they want to exercise, but they just can't find the time. The solution just might be in-office interval training. Recent studies show that very short but intense exercise rapidly builds and maintains fitness and health, even when the workout is only a few minutes long. Work the stairs You can complete an excellent, effective -- and very brief -- workout in an office stairwell, says Martin Gibala, a professor of kinesiology at McMaster University in Canada and an expert on interval training. For a study that he and his colleagues presented earlier this year, they asked 12 out-of-shape women in their 20s to warm up for two minutes by slowly walking up and down stairs in a campus office building. They completed three of these abbreviated stair workouts per week for six weeks. By the end, their aerobic fitness had improved substantially, the researchers reported, by about as much as if they had been running or cycling each week for hours. Fidget your way to fitness. Parents and teachers may once have urged you to sit still, but wiggling, tapping your toes, standing briefly, and otherwise fidgeting as much as possible at your desk is in fact good for your body. In one recent study, college students showed healthier blood flow in their lower legs if they fidgeted than if they did not. Even better, a 2008 study found that among office workers, those who frequently fidgeted burned as many as 300 calories more each day than those who resolutely stayed still.
[EX A]: How many studies are shown in the passage?

[EX Q]: Australia has promised to introduce the most comprehensive carbon trading program outside Europe in 2010. The government in Canberra plans to cut greenhouse gas emissions by at least five percent by 2020, but it could make bigger reductions if other countries agree to tougher targets. The Australian government warns that without tough environmental measures the country could lose key industries and jobs. Climate Change Minister Penny Wong says the economy is under threat and decisive action is needed. Central to the government's climate change plan is a carbon emissions trading program that will be introduced within two years. It would involve one thousand of the nation's biggest companies and would cover about three-quarters of Australia's greenhouse gas emissions. Many scientists believe that greenhouse gases, such as carbon dioxide and methane, contribute to global warming. Many of them are released by burning fuels such as coal and oil. Companies will be required to buy permits for each ton of carbon they emit, although big polluting exporters will receive up to 90 percent of their carbon licenses free. Many business leaders want the government to delay the plan because of the current global financial crisis, which is slowing the Australian economy. Peter Anderson from the Australian Chamber of Commerce and Industry says it is irresponsible to bring in a carbon trading plan now. Environmentalists, on the other hand, say Prime Minister Kevin Rudd has not properly addressed the threat of climate change. Activists had sought a minimum emissions cut of 25 percent. Instead, the Rudd government aims to cuts carbon emissions by at least five percent of 2000 levels by 2020. That amount could rise to 15 percent, if future global agreements set such a target. Ray Nias of the environmental group WWF says Australia will pay the price for low targets. "This is a deeply, deeply disappointing target," Nias said. "It commits Australia to long-term climate change. It will make Australia's ability to negotiate global agreements very, very difficult. It is much lower than even we had imagined." Australia has one of the highest per-person greenhouse emissions rates in the world because of its reliance on coal for electricity. _
[EX A]: Who most probably agrees to a higher goal of carbon emissions?

[EX Q]: Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis. In this randomized, placebo-controlled, multinational clinical trial, we assigned 481 patients (nearly all of whom were negative for the human immunodeficiency virus) with pulmonary multidrug-resistant tuberculosis to receive delamanid, at a dose of 100 mg twice daily (161 patients) or 200 mg twice daily (160 patients), or placebo (160 patients) for 2 months in combination with a background drug regimen developed according to World Health Organization guidelines. Sputum cultures were assessed weekly with the use of both liquid broth and solid medium; sputum-culture conversion was defined as a series of five or more consecutive cultures that were negative for growth of M. tuberculosis. The primary efficacy end point was the proportion of patients with sputum-culture conversion in liquid broth medium at 2 months. Among patients who received a background drug regimen plus 100 mg of delamanid twice daily, 45.4% had sputum-culture conversion in liquid broth at 2 months, as compared with 29.6% of patients who received a background drug regimen plus placebo (P=0.008). Likewise, as compared with the placebo group, the group that received the background drug regimen plus 200 mg of delamanid twice daily had a higher proportion of patients with sputum-culture conversion (41.9%, P=0.04). The findings were similar with assessment of sputum-culture conversion in solid medium. Most adverse events were mild to moderate in severity and were evenly distributed across groups. Although no clinical events due to QT prolongation on electrocardiography were observed, QT prolongation was reported significantly more frequently in the groups that received delamanid. Delamanid was associated with an increase in sputum-culture conversion at 2 months among patients with multidrug-resistant tuberculosis. This finding suggests that delamanid could enhance treatment options for multidrug-resistant tuberculosis. (Funded by Otsuka Pharmaceutical Development and Commercialization; ClinicalTrials.gov number, NCT00685360.).
[EX A]:
Which disease can be treated with Delamanid?